Replies to post #103 on Nuvectra Corp. (fka NVTRQ)

[joseytheoutlawwales]

I think in this space there is ALWAYS the chance for a buyout; i.e. st Jude purchase by Abbott.
Management is younger with NVTR, so likely they are looking to grow the company.
BUT, for the right price I'd bet they'd take a buyout.
I see larger pharmacy getting involved in the stim space to a much greater degree within the next 5-10 years.

Abbott bought St Jude, GSK and Google formed Galvani Bioelectronics (still private and in R&D, but BUY BUY BUY if they ever go public).
Other rumors abound.

It's partially why I'll always hold a core share position.
I feel a good product valuation (not current revenue value, but potential) for NVTR is ranged between 750 million to 2 billion.
With NVTR 10.34 million O/S the math adds up to a VERY nice number.